AD-5423 Dainippon Pharmaceutical Co Ltd.
AD-5423, a D(2)/5-HT2 antagonist, is in phase II clinical trials by Dainippon for the treatment of schizophrenia and other psychoses. In a phase I study of AD-5423 in eight healthy volunteers, it appeared to be well-tolerated and failed to induce extra pyramidal side effects, excessive sedation or hypotension [181465]. Analysts at Yamaichi estimate that AD-5423 will be launched in Japan in 1999 and annual sales will be less than five billion Yen [216018].
Heading
C E
CE